tirzepatide cardiovascular outcome trial cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says tirzepatide outcomes trial results – tirzepatide cardiovascular outcomes trial linked

The efficacy and safety of tirzepatide, with a special focus on cardiovascular safety, were investigated in the 52-week SURPASS-4 trial testing tirzepatide versus insulin glargine in adults with T2D and a high cardiovascular risk under inadequate glycemic control at baseline on one to three oral glucose-lowering medications (metformin, sulfonylurea, SGLT-2 inhibitor) (74)

That means some patients are now paying more, making treatment harder to afford

These data are consistent with one of two scenarios, either (1) direct peptide-stimulated inhibition of GLP-1R and Y1-R on -cells, or (2) indirect peptide-mediated insulin release leading to inhibition of glucagon release, as observed in previous studies 50,51

(PubMed) Bermingham EN, Hesketh JE, Sinclair BR, Koolaard JP, Roy NC

Weeks thirteen through sixteen continue the escalation to 1.7 mg